2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Molecular Testing, Omics Technologies, Pathology, Bioinformatics, Computational Biology, Emerging Technologies, Profiling, Treatment Considerations, Combination Therapy, Supportive Care, Biological Therapies, Antibody Therapy, Natural Killer (NK) Cell Therapies, Transplantation, (CAR)-T Cell Therapies, Immunotherapy, Non-Biological Therapies, Chemotherapy, Artificial Intelligence (AI), Machine Learning, Biological Processes, Apoptosis, Pathogenesis, Genomics, Immune Mechanism, Metabolism, Molecular Biology, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Clinical Guidelines, Practice Models, Systems-Based Hematology, Diseases, Bone Marrow Failure Syndromes, Acquired Marrow Failure Syndromes , Genetic Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, Research, Fundamental Science, AML, Translational Research, MDS, MPN, Clinical Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly, Pediatric, Young Adult
PAPER

1704 Development and characterization of a novel acute myeloid leukemia (AML) cell line with de novo KRAS/asxl-1 co-mutations and refractory to T-cell cytotoxicity

Parveen Shiraz, MD, Sonia Fonseca, BS2, Kathy Phuong Le, MS3, Carlos Jose Rodriguez Santiago, MS4, Jessica Poyser, BS5, Hao Yan, PhD6, Bita Sahaf, PhD7, Moksha Desai, MS8, Zachary Ehlinger, MS9, Bing Zhang, MD10, David Miklos, MD, PhD11, Vanessa E Kennedy, MD12, Judith Anne Shizuru, MD, PhD13
1 Stanford University, Stanford, California, United States
2 Stanford University, Stanford, California, United States
3 Stanford University, Stanford, California, United States
4 Stanford University, Stanford, California, United States
5 Stanford University, Stanford, California, United States
6 Stanford University, Stanford, California, United States
7 Stanford University, Stanford, California, United States
8 Stanford University, Stanford, California, United States
9 Stanford University, Stanford, California, United States
10 Stanford University, Stanford, California, United States
11 Stanford University, Stanford, California, United States
12 Stanford University, Stanford, California, United States
13 Stanford University, Stanford, California, United States

Introduction

AML is genetically and molecularly heterogenous. Novel precision medicine strategies are needed to improve outcomes. A wide range of patient derived cell lines with unique genetic and phenotypic characteristics are needed to study mechanisms of drug resistance, extramedullary growth and immune escape after hematopoietic stem cell transplant (HCT) and cell therapy. We developed and characterized a novel, patient derived AML cell line STSL-7, with concurrent ASXL-1/KRAS mutations, BCL2L1 amplification, and several novel antigenic targets for immunotherapy. Given the growing literature on RAS associated extramedullary disease (EMD), RAS mediated drug resistance in FLT3 and ASXL-1 mutated AML, and BCL2 mediated resistance to venetoclax, STSL-7 can be a valuable tool in advancing our understanding of these mechanisms. 

Methods

STSL-7 is a primary patient-derived AML cell line developed from ascitic fluid blast cells from a patient with MDS transformed to AML with EMD relapse occurring 60 days after myeloablative HCT. Comprehensive molecular and functional characterization of STSL-7 was performed using tissue culture, multiparametric flow cytometry (MPFC), mass spectrometry (MS), karyotyping, FISH, mutational analysis with next generation sequencing (NGS), and cellular indexing of transcriptomes and epitopes by sequencing (CITE-Seq). In vivo xenograft mouse models were established in immunodeficient NBSGW mice with and without low dose radiation (XRT).

Results

In standard cell culture media without cytokines, STSL-7 cells grew exponentially, doubling every 48-72 hours, with >90% viability and for >50 passages despite several freeze-thaw cycles, thus demonstrating immortality. On MPFC, at passage(P)6, STSL-7 was positive for CD34, CD33, CD13, CD47, CD123, CD38, CD135 (low), CD117 (low), HLA-A/B/C, HLA-DR/DP/DQ (low), PDL2 (CD273) (low), CD155, CD90 (low), CD45RA (low), CD41a, and negative for CD3, CD4, CD8, CD20, CD7, CD70, CD112, CD80, CD86, PDL1 (CD274), with this phenotype persisting at late P50. Cytogenetic analysis at early and late passages, showed complex karyotype in all 20 cells with add(1p), add(6p), +8, +6, +12, +19, +21, del20, der(17)t(1;17)] and 1~5 additional marker chromosomes. On FISH, 192/200 cells (96%) were positive for BCL2L1 amplification. NGS on early and late passages showed 2 driver mutations: 1) KRAS variant c.34G>T (p.Gly12Cys) with 55% variant allele frequency (VAF) at P0 and 62% VAF at P32 and 2) ASXL1 variant c.1934dup (p.Gly646fs) with 18% VAF at P0 and 16% at P32. Additional variants of unknown significance were detected in RUNX1, CBL, KIT, EZH2, PPM1D and TNFRSF.  Surface proteomics MS showed expression of >3900 molecules, including several integrin molecules potentially responsible for cell adhesion and EMD, and novel antigens for immunotherapy including CALR, CD37, CD200, CD300a, CD82, and FUT4.

STSL-7 showed considerable transcriptional heterogeneity on CITE-seq. With increasing passaging, cells became less stem-like and exhibited more megakaryocytic, monocytic, and erythroid features, and HLA loss. Pathway and network analysis demonstrated downregulation of cell adhesion and inflammatory signatures, including TCR/BCR activation, TNF signaling, and natural killer (NK) cell-associated toxicity, indicating progressive transcriptional evolution despite relatively stable molecular features.

STSL-7 cells were injected into 12 NBSGW mice, 6 with and 6 without pre-conditioning 50cGy XRT. Engraftment was detected at 4 weeks with 0.5% human(h)CD45 peripheral blood chimerism (chim) in both cohorts with progressive increase in peripheral blood hCD45 chim until 12 weeks at which time 2 of 12 of mice died and the other 10 appeared moribund. Blood, bone marrow and spleen from the 10 mice showed 40-60% hCD45 chim, >90% of hCD45 being hCD34+ blasts confirming progressive leukemia. In vitro, STSL-7 cells were resistant to killing by T cells with CD33 targeting T-cell engager (TCE) but susceptible to NK mediated lysis.

Conclusion

STSL-7 is a novel, primary patient derived, KRAS/ASXL-1 co-mutated extramedullary AML cell line. Despite high-risk mutations and complex karyotype, STSL-7 is highly susceptible to NK mediated cytotoxicity, but resistant to T-cell mediated killing. STSL-7 is a potentially valuable tool to study mechanisms of EMD, AML resistance to TCE and CAR-T cell therapy, RAS and BCL-2 mediated resistance to targeted therapy, and to advance studies of NK cell therapy in adverse risk AML.

Parveen Shiraz, MD: No relevant conflicts of interest to declare.